Redeye raises the DMS volume assumptions, consequently upping the base case. Our conviction regarding the case and the long-term trajectory remains rock solid. However, we expect a short-term drop from profit taking, following a surge of about 70% during the past two months.
Read more and download the Research Update
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.